Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.48 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254472 | 0.95 | ROCK2 (0.71) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| SCHEMBL10036305 | 0.83 | ROCK2 (1.00) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| SCHEMBL5256424 | 0.83 | ROCK2 (0.67) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| SCHEMBL12218261 | 0.74 | RAB9A (0.76) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| SCHEMBL12218264 | 0.74 | RAB9A (0.76) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| SCHEMBL715864 | 0.73 | ROCK2 (0.75) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| SCHEMBL10036311 | 0.73 | ROCK2 (0.76) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| Hydrochloric Acid SCHEMBL4523617 | 0.72 | RAB9A (0.73) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| SCHEMBL5308148 | 0.72 | ROCK2 (0.73) | ROCK2CYP1A2RAB9ANPC1CYP3A4 | |
| SCHEMBL720201 | 0.72 | ROCK2 (0.77) | ROCK2CYP1A2RAB9ANPC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20050209261-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-22 | — | — | US | disclosed |
| US-6943172-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040002507-A1 | Rho-kinase inhibitors | BAYER CORPORATION (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002507-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP1A2 1810/4885RAB9A 272/4885 |
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP1A2 1810/4885RAB9A 272/4885 |
| US-20050209261-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP1A2 1810/4885RAB9A 272/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | ROCK2 3/4885CYP1A2 1810/4885RAB9A 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.